Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination

被引：28

作者：

Ha, Sang-Jun

Park, Su-Hyung

Kim, Hye-Ju

Kim, Seung-Chul

Kang, Hyang-Ju

Lee, Eun-Gae

Kwon, Soon-Geon

Kim, Byong-Moon

Lee, Sung-Hee

Kim, Won-Bae

Sung, Young-Chul

Cho, Sang-Nae

机构：

[1] Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea

[2] Yonsei Univ, Coll Med, Project Med Sci Brain Korea 21, Seoul 120752, South Korea

[3] Pohang Univ Sci & Technol, Div Mol & Life Sci, Postech Biotech Ctr, Pohang 790784, South Korea

[4] Dong A Pham Co Ltd, Res Labs, Yongin 449900, Kyunggi Do, South Korea

[5] Int Vaccine Inst, Seoul 151600, South Korea

来源：

INFECTION AND IMMUNITY | 2006年 / 74卷 / 08期

关键词：

D O I：

10.1128/IAI.01781-05

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.

引用

页码：4954 / 4959

页数：6

共 31 条

[1]

ANACKER RL, 1967, J IMMUNOL, V98, P1265

[2] Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].